Preclinical Data: Telomir-Zn Restores Insulin Sensitivity, Bolstering Diabetes Potential
TELO sits 21% above its 52-week low of $1.05.
Summary
Telomir Pharmaceuticals announced compelling preclinical data for Telomir-Zn, showing it restored insulin sensitivity and improved glucose control in a Type 2 diabetes model. This peer-reviewed publication, detailing significant reductions in fasting blood glucose and HOMA-IR, provides strong scientific validation for the drug. The news expands the potential market for Telomir-Zn, which recently received IND clearance for a Phase 1/2 trial in triple-negative breast cancer, offering a positive development amidst the company's ongoing financial challenges.
At the time of this announcement, TELO was trading at $1.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $86.7M. The 52-week trading range was $1.05 to $3.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.